Daily non-political popular news in brief.
Radiation plus chemo quadruples survival time for fatal brain cancer
10-29-2007 · EurekAlert!Over four times as many patients with a rapidly fatal type of brain cancer, glioblastoma multiforme, who are treated with the chemotherapy drug temozolomide and radiation therapy, can live for four years after diagnosis, compared to those who receive only radiation treatment, according to updated results of a large, international trial presented at the Plenary I session on Oct. 29, 2007, at the American Society for Therapeutic Radiology and Oncology's 49th Annual Meeting in Los Angeles.
Read more »
Keywords: radiation, plus, chemo, quadruples, survival, time, fatal, brain, cancer, plu, quadruple
« Previous | Next »
Similar news on "Radiation plus chemo quadruples survival time for fatal brain cancer":
- Radiation after surgery doubles survival time for some lung cancer patients
11-06-2006 · EurekAlert!
Patients with lung cancer that has spread to mediastinal lymph nodes -- located between the chest, breastbone and spine -- who receive radiation after surgery and chemotherapy live twice as long as patients who do not receive radiation after surgery, according to a study presented at the plenary session November 6, 2006, at the American Society for Therapeutic Radiology and Oncology's 48th Annual Meeting in Philadelphia.
Similar news · Read more »
- Treatment capitalizes on unique qualities of radioisotope to prolong lives of brain tumor patients
01-30-2008 · EurekAlert!
In a study to determine safe dosages of the isotope astatine-211 for patients with recurring brain tumors, researchers were pleasantly surprised to find that not only was the isotope's potency sufficient to kill residual cancer cells without damaging sensitive healthy brain cells, but the patients experienced longer survival rates.
Similar news · Read more »
- Additional hormone therapy use after radiation for some prostate cancers extends survival
11-06-2006 · EurekAlert!
The largest study examining the benefits of long-term use of hormone therapy after radiation treatment for prostate cancer shows men with aggressive locally advanced disease live longer if hormones are used for an additional 24 months. Research also showed other significant benefits for those with less aggressive cancers who receive hormones.
Similar news · Read more »
- Prophylactic cranial irradiation in small cell lung cancer significantly increases survival
08-16-2007 · EurekAlert!
Prophylactic cranial irradiation after chemotherapy significantly reduces the risk of brain metastasis and doubles one-year survival in small-cell lung cancer, according to the results of the multicenter phase III randomized EORTC trial 08993-22993, published in the New England Journal of Medicine today.
Similar news · Read more »
- Blood-vessel blocker aids cancer-killing virus
11-27-2007 · EurekAlert!
Cancer-killing viruses are a promising therapy for incurable brain tumors, but their effectiveness has been limited in part because immune cells rapidly eliminate them. That immune response might be slowed, and the virus given more time to kill cancer cells, by blocking the growth of blood vessels in the tumor, new Ohio State research suggests. The study indicates that pretreatment with a drug that blocks blood-vessel growth might improve the effectiveness of cancer-killing viruses.
Similar news · Read more »
- Mayo Clinic Cancer Center -- Surgery and adjuvant therapy may work for pancreatic cancer
01-20-2007 · EurekAlert!
In the largest single-institution retrospective study to date, researchers at Mayo Clinic Cancer Center have shown that giving patients both radiation and chemotherapy after completely removing invasive pancreatic cancer may improve overall survival rates.
Similar news · Read more »
- Gene thought to assist chemo may help cancer thrive
05-15-2007 · EurekAlert!
A gene thought to be essential in helping chemotherapy kill cancer cells, may actually help them thrive. In a new study of chemo patients, scientists at Georgia Tech and the Ovarian Cancer Institute found that 70 percent of subjects whose tumors had mutations in the gene p53 were still alive after five years. Patients with normal p53 displayed only a 30 percent survival rate.
Similar news · Read more »
- Does neural cell adhesion molecule-180 predict survival in colorectal cancer?
11-02-2007 · EurekAlert!
As cancer is one of the most fatal diseases worldwide, tumor markers and prognostic criterions are of great interest to researchers. Tumor suppressors and cell adhesion molecules play crucial roles in tumor pathophysiology, acting as potential targets for treatment modalities. NCAM-180 is a structural molecule that mediates cell-cell adhesion, resulting in tissue stabilization. It has been proposed as a tumor suppressor in colon carcinoma. A research group in Turkey has investigated the prognostic value of NCAM-180 in colorectal cancer.
Similar news · Read more »
- Common cancer treatments toxic to healthy brain cells
11-29-2006 · EurekAlert!
Common drugs used to treat cancer may be more harmful to healthy brain cells than the cancer cells that they are intended to destroy, according to a new study. The results, which also indicate that chemotherapy may cause long-term brain damage, represent the closest that scientists have come to pinpointing the underlying physiological cause of "chemo brain," a common side effect of cancer treatment that scientists are only now beginning to comprehend.
Similar news · Read more »
- Drug study for brain cancer shows promising results
12-13-2007 · EurekAlert!
A clinical study conducted at Henry Ford Hospital on the use of a drug to extend the survival of patients with the most common and aggressive type of brain cancer, has yielded results that were significantly better than expected.
Similar news · Read more »
